127 related articles for article (PubMed ID: 23237005)
21. Salvage of locally recurrent prostate cancer after external beam radiation using reduced-dose brachytherapy with neoadjuvant plus adjuvant androgen deprivation.
Baumann BC; Baumann JC; Christodouleas JP; Soffen E
Brachytherapy; 2017; 16(2):291-298. PubMed ID: 28139422
[TBL] [Abstract][Full Text] [Related]
22. The relationship between the biochemical control outcomes and the quality of planning of high-dose rate brachytherapy as a boost to external beam radiotherapy for locally and locally advanced prostate cancer using the RTOG-ASTRO Phoenix definition.
Pellizzon AC; Salvajoli J; Novaes P; Maia M; Fogaroli R; Gides D; Horriot R
Int J Med Sci; 2008 Jun; 5(3):113-20. PubMed ID: 18566673
[TBL] [Abstract][Full Text] [Related]
23. Propensity-weighted long-term risk of urinary adverse events after prostate cancer surgery, radiation, or both.
Jarosek SL; Virnig BA; Chu H; Elliott SP
Eur Urol; 2015 Feb; 67(2):273-80. PubMed ID: 25217421
[TBL] [Abstract][Full Text] [Related]
24. Radical radiotherapy for prostate cancer: patterns of care in Sweden 1998-2016.
Beckmann K; Garmo H; Nilsson P; Franck Lissbrant I; Widmark A; Stattin P
Acta Oncol; 2020 May; 59(5):549-557. PubMed ID: 32122185
[No Abstract] [Full Text] [Related]
25. Dosimetric considerations to determine the optimal technique for localized prostate cancer among external photon, proton, or carbon-ion therapy and high-dose-rate or low-dose-rate brachytherapy.
Georg D; Hopfgartner J; Gòra J; Kuess P; Kragl G; Berger D; Hegazy N; Goldner G; Georg P
Int J Radiat Oncol Biol Phys; 2014 Mar; 88(3):715-22. PubMed ID: 24521685
[TBL] [Abstract][Full Text] [Related]
26. A Systematic Post-QUANTEC Review of Tolerance Doses for Late Toxicity After Prostate Cancer Radiation Therapy.
Olsson CE; Jackson A; Deasy JO; Thor M
Int J Radiat Oncol Biol Phys; 2018 Dec; 102(5):1514-1532. PubMed ID: 30125635
[TBL] [Abstract][Full Text] [Related]
27. Prostate cancer radiation and urethral strictures: a systematic review and meta-analysis.
Awad MA; Gaither TW; Osterberg EC; Murphy GP; Baradaran N; Breyer BN
Prostate Cancer Prostatic Dis; 2018 Jun; 21(2):168-174. PubMed ID: 29296018
[TBL] [Abstract][Full Text] [Related]
28. Toxicity and clinical outcomes of single-fraction high-dose-rate brachytherapy combined with external beam radiotherapy for high-/very high-risk prostate cancer: A dosimetric analysis of toxicity.
Sakurai T; Takamatsu S; Shibata S; Iwata K; Taka M; Gabata T; Kumano T; Makino T; Mizokami A
Jpn J Radiol; 2020 Dec; 38(12):1197-1208. PubMed ID: 32737768
[TBL] [Abstract][Full Text] [Related]
29. Brachytherapy improves biochemical failure-free survival in low- and intermediate-risk prostate cancer compared with conventionally fractionated external beam radiation therapy: a propensity score matched analysis.
Smith GD; Pickles T; Crook J; Martin AG; Vigneault E; Cury FL; Morris J; Catton C; Lukka H; Warner A; Yang Y; Rodrigues G
Int J Radiat Oncol Biol Phys; 2015 Mar; 91(3):505-16. PubMed ID: 25596107
[TBL] [Abstract][Full Text] [Related]
30. Salvage radiotherapy for rising prostate-specific antigen levels after radical prostatectomy for prostate cancer: dose-response analysis.
Bernard JR; Buskirk SJ; Heckman MG; Diehl NN; Ko SJ; Macdonald OK; Schild SE; Pisansky TM
Int J Radiat Oncol Biol Phys; 2010 Mar; 76(3):735-40. PubMed ID: 19464818
[TBL] [Abstract][Full Text] [Related]
31. Prostate-only Versus Whole-pelvis Radiation with or Without a Brachytherapy Boost for Gleason Grade Group 5 Prostate Cancer: A Retrospective Analysis.
Sandler KA; Cook RR; Ciezki JP; Ross AE; Pomerantz MM; Nguyen PL; Shaikh T; Tran PT; Stock RG; Merrick GS; Demanes DJ; Spratt DE; Abu-Isa EI; Wedde TB; Lilleby W; Krauss DJ; Shaw GK; Alam R; Reddy CA; Song DY; Klein EA; Stephenson AJ; Tosoian JJ; Hegde JV; Yoo SM; Fiano R; D'Amico AV; Nickols NG; Aronson WJ; Sadeghi A; Greco SC; Deville C; McNutt T; DeWeese TL; Reiter RE; Said JW; Steinberg ML; Horwitz EM; Kupelian PA; King CR; Kishan AU
Eur Urol; 2020 Jan; 77(1):3-10. PubMed ID: 30992160
[TBL] [Abstract][Full Text] [Related]
32. A method to estimate composite doses for organs at risk in prostate cancer patients treated with EBRT in combination with HDR BT.
Pettersson N; Johansson KA; Alsadius D; Tucker SL; Steineck G; Olsson C
Acta Oncol; 2014 Jun; 53(6):815-21. PubMed ID: 24460070
[TBL] [Abstract][Full Text] [Related]
33. A comparative study of high-dose-rate brachytherapy boost combined with external beam radiation therapy versus external beam radiation therapy alone for high-risk prostate cancer.
Oshikane T; Kaidu M; Abe E; Ohta A; Saito H; Nakano T; Honda M; Tanabe S; Utsunomiya S; Sasamoto R; Ishizaki F; Kasahara T; Nishiyama T; Tomita Y; Aoyama H; Ishikawa H
J Radiat Res; 2021 May; 62(3):525-532. PubMed ID: 33823010
[TBL] [Abstract][Full Text] [Related]
34. Rectal bleeding after high-dose-rate brachytherapy combined with hypofractionated external-beam radiotherapy for localized prostate cancer: the relationship between dose-volume histogram parameters and the occurrence rate.
Okamoto M; Ishikawa H; Ebara T; Kato H; Tamaki T; Akimoto T; Ito K; Miyakubo M; Yamamoto T; Suzuki K; Takahashi T; Nakano T
Int J Radiat Oncol Biol Phys; 2012 Feb; 82(2):e211-7. PubMed ID: 21620579
[TBL] [Abstract][Full Text] [Related]
35. Impact of the target volume (prostate alone vs. prostate with seminal vesicles) and fraction dose (1.8 Gy vs. 2.0 Gy) on quality of life changes after external-beam radiotherapy for prostate cancer.
Pinkawa M; Piroth MD; Fischedick K; Holy R; Klotz J; Nussen S; Krenkel B; Eble MJ
Strahlenther Onkol; 2009 Nov; 185(11):724-30. PubMed ID: 19899005
[TBL] [Abstract][Full Text] [Related]
36. Direct 2-arm comparison shows benefit of high-dose-rate brachytherapy boost vs external beam radiation therapy alone for prostate cancer.
Khor R; Duchesne G; Tai KH; Foroudi F; Chander S; Van Dyk S; Garth M; Williams S
Int J Radiat Oncol Biol Phys; 2013 Mar; 85(3):679-85. PubMed ID: 22954770
[TBL] [Abstract][Full Text] [Related]
37. Health-related Quality of Life and Toxicity After Single-fraction High-dose-rate Brachytherapy With External Beam Radiotherapy for Localized and Locally Advanced Prostate Cancer.
Makino T; Nakashima K; Iijima M; Kawaguchi S; Nohara T; Shigehara K; Izumi K; Kadono Y; Kumano T; Mizokami A
Anticancer Res; 2019 Jan; 39(1):477-486. PubMed ID: 30591498
[TBL] [Abstract][Full Text] [Related]
38. Comparison of the outcome and morbidity for localized or locally advanced prostate cancer treated by high-dose-rate brachytherapy plus external beam radiotherapy (EBRT) versus EBRT alone.
Fang FM; Wang YM; Wang CJ; Huang HY; Chiang PH
Jpn J Clin Oncol; 2008 Jul; 38(7):474-9. PubMed ID: 18621848
[TBL] [Abstract][Full Text] [Related]
39. Pain and mean absorbed dose to the pubic bone after radiotherapy among gynecological cancer survivors.
Waldenström AC; Olsson C; Wilderäng U; Dunberger G; Lind H; al-Abany M; Palm Å; Avall-Lundqvist E; Johansson KA; Steineck G
Int J Radiat Oncol Biol Phys; 2011 Jul; 80(4):1171-80. PubMed ID: 20643516
[TBL] [Abstract][Full Text] [Related]
40. Patient-reported outcomes and health-related quality of life in prostate cancer treated with a single fraction of high dose rate brachytherapy combined with hypofractionated external beam radiotherapy.
Choudhury A; Arthur C; Malik J; Mandall P; Taylor C; Alam N; Tran A; Livsey J; Elliott T; Davidson S; Logue JP; Wylie J
Clin Oncol (R Coll Radiol); 2014 Oct; 26(10):661-7. PubMed ID: 25027670
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
